Eton Pharmaceuticals logo

Eton Pharmaceuticals

ETON | NASDAQ
Chart Builder DCF Calculator
$63.88
-$0.05 (-0.08%)
At close: Nov 16, 2026, 4:00 PM ET
$63.77
-$0.11 (-0.17%)
After-hours: Nov 16, 2026, 7:52 PM ET
-0.08%

Rating

Updated: Nov 16, 2026
80.9
Fundamentals Excellent
Market Sentiment Bullish
Moat Narrow
Sector Rank #17/1021 (Top 2%)

Key Statistics

Market Data

Market Cap $1.84B
1D Range
63.50 66.73
52W Range
14.35 68.40

Valuation (TTM)

PE 42.30
PB 21.20
EV/EBITDA 40.75

Valuation (NTM)

Forward PE 31.81
Forward PEG 0.08
Price Target $70.00
Loading financial charts...

Profile

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of...

Sector Healthcare
Employees 44
IPO Date Nov 14, 2018
Fiscal Year January - December

Latest News

Eton Pharmaceuticals: The Commercial Model Is Finally Scaling

18 hours ago · seekingalpha.com

Eton Pharmaceuticals: The Commercial Model Is Finally Scaling
Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion

11 days ago · zacks.com

Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion
Eton Pharmaceuticals Q3 Earnings Call Highlights

11 days ago · marketbeat.com

Eton Pharmaceuticals Q3 Earnings Call Highlights
Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript

11 days ago · seekingalpha.com

Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q3 Earnings and Revenues Surpass Estimates

11 days ago · zacks.com

Eton Pharmaceuticals, Inc. (ETON) Q3 Earnings and Revenues Surpass Estimates
ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?

15 days ago · zacks.com

ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026

19 days ago · globenewswire.com

Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

1 month ago · globenewswire.com

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
ETON Stock Surges 108% in Six Months: Here's What You Need to Know

1 month ago · zacks.com

ETON Stock Surges 108% in Six Months: Here's What You Need to Know
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules

2 months ago · globenewswire.com

Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules

Earnings

Latest Earnings
Nov 5, 2026
EPS
$0.5
Beat +60.00%
REV
$57.93M
Beat +37.97%
Next Earnings
Mar 18, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
4
Consensus
Buy
Price Target
$70.00
Upside
+9.58%
Buy (4)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.